| Title |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies
|
|---|---|
| Published in |
Medical Oncology, June 2012
|
| DOI | 10.1007/s12032-012-0263-3 |
| Pubmed ID | |
| Authors |
Mario Balducci, Alba Fiorentino, Pasquale De Bonis, Silvia Chiesa, Stefania Manfrida, Giuseppe Roberto D’Agostino, Giovanna Mantini, Vincenzo Frascino, Gian Carlo Mattiucci, Berardino De Bari, Annunziato Mangiola, Francesco Miccichè, Maria Antonietta Gambacorta, Gabriella Colicchio, Alessio Giuseppe Morganti, Carmelo Anile, Vincenzo Valentini |
| Abstract |
To analyse the impact of age and co-morbidities on compliance and outcomes in GBM patients enrolled in three prospective phase II trials. GBM patients (≥ 18 years) were treated with radiotherapy (60 Gy) or enrolled in a Fractionated Stereotactic Conformal-Radiotherapy Phase II trial (69.4 Gy). Concomitant and adjuvant chemotherapy with Temozolomide (TMZ) was administered. Charlson Index Co-morbidity (CCI) was used to assess co-morbidity. Toxicity was evaluated according to RTOG score. Survival analysis was performed by the Kaplan-Maier. Influence of age and co-morbidity was evaluated using log-rank test. From 2001 to 2008, 146 patients were enrolled: 56 (38.4 %) aged over 65 and 90 under 65. CCI ≥ 1 was observed in 41 % of elderly and 22 % of young group. Patients' compliance was 97.9 % for radio-chemotherapy. Acute toxicity was mild with no difference between the groups. Global median progression-free survival (PFS) and overall survival (OS) were 12 and 18 months, respectively. Age, surgery and radiation dose correlated with survival (p = 0.01, p = 0.04 and p = 0.03). CCI ≤ 2 did not show any influence on OS. Our data show that elderly with a good performance status and few co-morbidity may be treated as younger patients; moreover, age confirms a negative impact on survival while CCI ≤ 2 did not correlated with OS. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| United States | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 70 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 16% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Postgraduate | 5 | 7% |
| Professor > Associate Professor | 5 | 7% |
| Student > Master | 5 | 7% |
| Other | 16 | 22% |
| Unknown | 24 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 42% |
| Neuroscience | 5 | 7% |
| Nursing and Health Professions | 2 | 3% |
| Social Sciences | 2 | 3% |
| Agricultural and Biological Sciences | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 28 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2012.
All research outputs
#15,246,403
of 22,669,724 outputs
Outputs from Medical Oncology
#631
of 1,280 outputs
Outputs of similar age
#106,333
of 166,843 outputs
Outputs of similar age from Medical Oncology
#9
of 20 outputs
Altmetric has tracked 22,669,724 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,280 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,843 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.